New drug duo shows promise for Tough-to-Treat blood cancers
NCT ID NCT03534323
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of two drugs, duvelisib and venetoclax, in 55 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or Richter's syndrome. Duvelisib blocks a protein that helps cancer cells survive, while venetoclax targets another survival protein. The goal is to see how many patients achieve complete remission. The trial is active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
duvelisib and venetoclax
What this could lead to
If successful, this combination could offer a new treatment option for people with hard-to-treat CLL or Richter's syndrome.
What could go wrong
This is an early-phase trial with only 55 participants, so results may not apply to everyone. The drugs can cause side effects like infections or low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Berkshire Medical Center
Pittsfield, Massachusetts, 01201, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Northern Light Eastern Maine Medical Center
Brewer, Maine, 04412, United States
-
University of Miami- Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States